Citi raised the firm’s price target on Johnson & Johnson to $274 from $250 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain “healthy” despite the recent volatility, the analyst tells investors in a research note. Citi’s top picks are iRhythm and Medtronic.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- 3 Best ETFs to Invest In, According to AI Analyst, 03/10/2026
- Johnson & Johnson treatment of multiple myeloma granted orphan designation
- Controversial Prasad leaving FDA, NYT reports
- DGRO vs. HDV: Which BlackRock iShares Dividend ETF Pays More Income?
- Johnson & Johnson confirms FDA approval of Tecvayli-Darzalex Faspro combination